ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics is exploring significant cost-cutting measures to conserve resources and raise capital, including potential divestment of product candidates, employee headcount reductions, and possibly "going dark" by suspending SEC reporting. CEO Stephen Glover and CFO Peter Wolfe have voluntarily accepted reduced compensation. Additionally, the company is considering broader strategic alternatives such as a sale of the company or its assets, or restructuring, to maximize shareholder value. This comes as Dr. Min Chul Park resigned from the Board of Directors for personal reasons.

ZyVersa Therapeutics reported a net loss of $(1.79) million for the three months ended March 31, 2026, an improvement from $(2.26) million in the prior year. Despite this, the company's cash position of $0.3 million and a working capital deficit of $14.1 million, coupled with an accumulated deficit of $139.4 million, raise substantial doubt about its ability to continue as a going concern. The company issued $1.0 million in convertible notes and warrants during the quarter to secure additional financing.